Name Alan C. Yeung
Country United States
Job Interventional Cardiologist

Other content(s) by This Operator

  1. Brachytherapy vs DES: Is the Answer in yet ?
  2. Bifurcation Stenoses: Is There a Solution in Sight ?
  3. Percutaneous Bypass: Rebirth as Treatment for CTO
  4. Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition with Tirofiban before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty(TIGER-PA) Pilot Trial
  5. What Are The Proper End Points for DES Trial
  6. ABT 578 Drug-Eluting Stents II: Preclinical Observations and the Clinical Trial Strategy for the Abbott ZoMax Stent
  7. Regional Photodynamic Therapy for Vulnerable Plaque Stabilization I: Antrin
  8. IVUS in Complex PCI
  9. What Are the Proper End Points for DES Trials?
  10. Technical Aspects and an Update on the EU and US ZOMAXX Clinical Trials
  11. Systemic Therapy: Pharmacologic Approach or Cell/Gene Therapy
  12. Is There a Safety Advantage in the PC Based DES Systems? Possible Mechanisms
  13. TAXUS Real-World Experience from ARRIVE Registry
  14. D2B: An Alliance for Quality
  15. What Makes Endeavor Different
  16. Bifurcation Stenting: Implications of the Norfic Study
  17. New Devices in Bifurcation Lesions: Do We Really Need One?
  18. New Technologies for Bifurcation: Main Vessel Centric vs Side-Branch Centric
  19. Endothelial Dysfunction Associated with DES: How Important?
  20. Optimizing the Role of New Anti-thrombotic Regimens in ACS - When, What and Why?
  21. Association between CYP2C19 Genotype and Adverse Clinical Outcomes among PCI Patients: A Meta-analysis
  22. Experiences of 2nd Generation OCT in Assessment of Complex Coronary Lesions; Can It Give Us Additive Useful Information?
  23. How to Teach and Train Innovation: US Approach
  24. Is It Real? Cytochrome P450 Genetic Polymorphisms, Varying Response to Clopidogrel, and Link to Clinical Outcomes : Global Perspective
  25. Use of OCT in Treating a LAD/Diagonal Bifurcation Lesion
  26. Clinical Decision Making in Patients with Left Main Disease
  27. The Updated Evidence-based Guidelines for the Use of Antiplatelet Therapies in ACS
  28. In-Stent Restenosis - Stop ISR: How to Treat DES-ISR?: Summary
  29. Promus-Element Stent
  30. Mediate a Dispute: Summary
  31. Invited Case Presentation & Focus Review: Multi-vessel Intervention
  32. Myocardial Bridge: Incidental Finding or Clinical Pathology?
  33. Coronary Obstruction: Treatment and Prevention
  34. Edward Sapien
  35. TAVI: Future Perspectives
  36. Edward Sapien: Transfemoral
  37. New Transcatheter Heart Valves
  38. Balloon Expandable System
  39. Complete Revascularization- The Future Mode of Revascularization in STEMI?
  40. Early Discharge Check List to Be Minimalist
  41. Frailty Assessment and How to Define Futile TAVR
  42. Next Issue: How to Manage Failed Transcatheter Heart Valve
  43. Low Coronary Ostium with Narrow or Wide Sinus
  44. TAVR: Advancing Your Skills: Beyond the Basics
  45. Comparative Outcomes of Contemporary DES; Are There Major Difference?
  46. Award Tribute
  47. MV and TV Intervention: Preparing for the Next Revolution
  48. Technical Lessons for TAVR; Expert Experience
  49. Sapien 3 or Evolut R: Different Indications?
  50. Experience, Current Status and Future of BRS in U.S. Real-World
  51. TAVR in Low Risk Patients
  52. The Evolution of Mitral and Tricuspid Valve Interventions: What It Is? and Where It Needs to Go?
  53. TAVR for Low Risk Patients: Interventionist\'s Viewpoint
  54. Sizing Strategy and PVL Management: Most Experienced Strategy
  55. PVL: How to Prevent and How to Treat?
  56. TAVR Clinical Trials
  57. TVT Registry
  58. MV and TV Repair - Current Status and Innovative Future
  59. Contemporary and Future Metallic DES: What Do We Expect More from Ongoing PCI Trials?
  60. Evolving TAVR Indications (Heart Failure, Asymptomatic AS, and AR)
  61. Contemporary DES Thrombosis and Restenosis: Incidence, Mechanisms, and Treatment
  62. Updates on Antiplatelet Therapy in Cardiovascular Disease
  63. How to Manage Complication TAVR Case
  64. Expert Case Review: PCI for Severely Calcified In-Stent Restenosis
  65. PCI, CABG, or Both: Current Status of Hybrid Coronary Revascularization
  66. Case 1: Complex LM/Multivessel Disease - Hybrid Revascularization
  67. Sapien 3 THV with Future Coronary Access
  68. Expanding Indication of TAVR: Ongoing Trials and Expectations
  69. Cerebral Protection During TAVR: Why and How?
  70. Many Many Stents: What Should I Select?
  71. Antithrombotic Strategy in PCI and AF Patients: Updated Strategy
  72. Optimal Valve Choice in Various TAVR: A Complex Equation to Select One